No Detail Found!

Efficacy and safety of eltrombopag in combination with rituximab in the treatment of immune thrombocytopenic purpura: A multicentre, randomised, open-label, prospective study

Author(s)
Yurong Zhang Department of Hematology, Siyang Hospital,Siyang, Suqian, Jiangsu,China
Haiyan Zhang Department of Hematology, Shuyang Hospital,Shuyang, Suqian, Jiangsu,China
Huirong Shan Department of Hematology, Shuyang Hospital,Shuyang, Suqian, Jiangsu,China
Yuyang Qi Department of Hematology, Nanjing Drum Tower Hospital Group Suqian Hospital,Suqian, Jiangsu,China
Yanyan Feng Department of Hematology, Sihong Hospital,Sihong, Suqian, Jiangsu,China
Sumei Wang Department of Hematology, Siyang Hospital,Siyang, Suqian, Jiangsu,China
Li Xu Department of Hematology, Siyang Hospital,Siyang, Suqian, Jiangsu,China
Wei Wei Department of Hematology, Siyang Hospital,Siyang, Suqian, Jiangsu,China
Shoudong Zhang Department of Hematology, Siyang Hospital,Siyang, Suqian, Jiangsu,China
Sha Chen Department of Hematology, Siyang Hospital,Siyang, Suqian, Jiangsu,China
Xiaohui Dai Department of Hematology, Siyang Hospital,Siyang, Suqian, Jiangsu,China
Abstract
This study aimed to evaluate the efficacy and safety of eltrombopag plus rituximab in the treatment of patients with immune thrombocytopenic purpura (ITP). Sixty ITP patients treated from September 2022 to September 2023 were recruited for this study, and were randomly divided into a control group and a treatment group. The former was given eltrombopag, and the later was given eltrombopag plus rituximab. The treatment efficacy, platelet levels, coagulation function, sustained effective SR, progression-free-survival, and incidence of adverse reactions and adverse events were compared in both groups using SPSS 22.0 statistical software. After nine months of treatment, the platelet level of the treatment group was significantly better than that of the control group (P0.05). In conclusion, eltrombopag combined with rituximab can effectively improve the efficacy of treatment in ITP patients, with high safety.
Publication Details
Page(s) 1656-1663
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 5, Year: 2025

Request the full text from PASTIC

Keywords
efficacy, Rituximab, Adverse event, Immune thrombocytopenic purpura, eltrombopag
References
Ata F,Yousaf Z,Zahir FZ,Mohamed Babiker A,Ali Farooqi A,Ahmad Al Hiyari M,Mohamed A I,Nashwan AH,Yassin AJ,MA AJ .2022 .. , : .
.2022 .Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population. Qatar Med, : 22.
Beltrami-Moreira M,Bussel JB. .2022 .Low-dose rituximab in immune thrombocytopenia: One and done. , : .
Hematol Am. J. . .. , 97(4) : 388-389.
Bolton-Maggs PHB,George JN .2021 .Immune thrombocytopenia treatment. N. Engl. J. Med, 385(10) : 948-950.
.2020 .(. Zhonghua Xue Ye Xue Za Zhi, 41(8) : 617-623.
Delshad M,Davoodi-Moghaddam Z,PourbagheriSigaroodi A,Faranoush M,Abolghasemi H,Bashash D H .2024 .Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials. Thromb. Res., 235 : 125-147.
DeSouza S and Angelini D.,September -October .2025 .Expanded management options. Cleve. Clin. J. Med, 88(12) : 664-668.
Hamed EM,Ibrahim ARN,Meabed MH,Khalaf AM,El Demerdash DM,Elgendy MO,Saeed H,Salem HF,Rabea H HF .2023 .Therapeutic outcomes of high dosedexamethasone versus prednisolone + azathioprine, rituximab, eltrombopag and romiplostim strategies in persistent, chronic, refractory and relapsed immune thrombocytopenia patients. Pharmaceuticals (Basel), 16(9) : 1215.
Kang H .2021 .Sample size determination and power analysis using the G*Power software. J. Educ. Eval., : .
Prof Health . .. , 18 : 17.
Kaur MN,Arnold DM,Heddle NM,Cook RJ,Hsia C,Blostein M,Jamula E,Sholzberg M,Lin Y,Kassis J,Larratt L,Tinmouth A,Carruthers J,Li N,Liu Y,Xie F Y .2022 .Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Adv., 6(3) : 785-792.
Kochhar M and Neunert C .2021 .Immune thrombocytopenia: A review of upfront treatment strategies. Blood Rev., 49 : 100822.
Li J,Guo J,Yuan R,Xue L R .2025 .Rituximab in Immune-mediated thrombotic thrombocytopenic purpura. Eur J Intern Med., : .
Hou Liu X G,Hou M Y .2023 .How we treat primary immune thrombocytopenia in adults. J. Hematol., : .
. .. , 16(1) : 4.
Nusrat S,Tewari S,Khan O .2023 .Successful treatment of lupus anticoagulant hypoprothrombinemia syndrome with rituximab. Thromb. J., 21(1) : 77.
Oliva EN,Riva M,Niscola P,Santini V,Breccia M,Giai V,Poloni A,Patriarca A,Crisà E,Capodanno I,Salutari P,Reda G,Cascavilla N,Ferrero D,Guarini A,Tripepi G,Iannì G,Russo E,Castelli A,Fattizzo B,Beltrami G,Bocchia M,Molteni A,Fenaux P,Germing U,Ricco A,Palumbo G A,Impera S,Di Renzo N,Rivellini F,Buccisano F,Stamatoullas-Bastard A,Liberati A M,Candoni A,Delfino IM,Arcadi MT,Cufari P,Rizzo L,Bova I,D'Errigo M G G,Latagliata R G .2023 .. , : .
. .Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: Interim results of a phase ii, randomized, placebo-controlled clinical trial (EQOLMDS). J. Clin. Oncol., 41(28) : 4486-4496.
Patel BA,Groarke EM,Lotter J,Shalhoub R,Rios F,Quinones Raffo O,Wu D,Young CO,NS. CO .2022 .Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: A phase 2 study. , 139(1) : 34-43.
Peffault de Latour R,Kulasekararaj A,Iacobelli S,Terwel SR,Cook R,Griffin M,Halkes CJM,Recher C,Barraco F,Forcade E,Vallejo J C,Drexler B,Mear JB,Smith AE,Angelucci E,Raymakers RAP,de Groot MR,Daguindau E,Nur E,Barcellini W,Russell N H,Terriou L,Iori A P,La Rocca U,Sureda A,Sánchez-Ortega I,Xicoy B,Jarque I,Cavenagh J,Sicre de Fontbrune F,Marotta S,Munir T,Tjon JML,Tavitian S,Praire A,Clement L,Rabian F,Marano L,Hill A,Palmisani E,Muus P,Cacace F,Frieri C,Lint MT,Passweg JR,Marsh JCW,Socie G,Mufti GJ,Dufour C,Risitano AM C .2022 .Eltrombopag added to immunosuppression in severe aplastic anemia. N. Engl. J. Med, 386(1) : 11-23.
Sandal R,Mishra K,Jandial A,Sahu KK,Siddiqui AD .2021 .Update on diagnosis and treatment of immune thrombocytopenia. Expert Rev. Clin. Pharmacol, 14(5) : 553-568.
Vianelli N,Auteri G,Buccisano F,Carrai V,Baldacci E,Clissa C,Bartoletti D,Giuffrida G,Magro D,Rivolti E,Esposito D,Podda GM,Palandri F GM .2022 .. , : .
. .. , 101(5) : 963-978.
.2021 .Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N. Engl. J. Med, 384(24) : 2295-2305.
Will B .2022 .Effects of eltrombopag on mesenchymal stem cells in immune thrombocytopenia purpura. Br. J., : .
. .. , 197(2) : 137-138.
Witkowski M,Ryżewska W,Robak T .2024 .. , : .
. .. , 35(3) : 108-114.
Zhang N,Ji C,Bao X,Yuan C .2022 .Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report. Medicine (Baltimore), 101(2) : e28417.
Zhou H,Fan J,He J,Hu S J .2022 .Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: A multiple-treatments network meta-analysis. , 101(5) : 953-961.
0

Citations

0

Downloads

84

Views